A former adversary of the DEA and HHS now shapes federal drug reform as Deputy General Counsel, steering executive orders and clinical access.

NORML files an amicus brief urging the Sixth Circuit to reconsider invalidating marijuana business contracts, warning of consumer safety risks.

Federal administrative law judge directs the Drug Enforcement Administration to address opponents' latest push for expanded testimony and discovery.

A new op-ed spotlights how Latino and immigrant workers power cannabis cultivation and retail—and why federal immigration policy and partial rescheduling still put them at risk.

DEA’s 2026 Drugs of Abuse update says no deaths from marijuana overdose and reflects federal moves toward Schedule III for certain cannabis products. Here’s what it means in practice.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

Congress advanced a delay to new hemp THC limits that would close the delta‑8 and THCA loopholes. Here’s how Section 781 touches delivery, products, and compliance in the DMV.

A DEA administrative law judge issued a stay on the wider adult-use rescheduling review, weighing a GAO report’s admission and extra briefing. The pause does not alter April’s medical marijuana move to Schedule III, per mg Magazine.

State regulators say DEA guidance is essential to align medical cannabis rules with the new Schedule III status—especially for delivery, labeling, and patient access across the DMV.

Federal lobbying hit record highs in Q2 2026 while the DEA targets tryptamines and Oregon reconsiders psilocybin program fees.

Four months after President Trump urged reclassification, DOJ made a partial move on cannabis scheduling. Here’s what it could mean for delivery laws and compliance.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

A new appellate decision threatens the enforceability of cannabis deals in federal court—and it reshapes leverage, drafting strategy, and risk for delivery, retail, and investors.

From Bicycle Day to modern art prints, here’s how LSD blotter design latched onto space themes—and why the revival matters for DC, Maryland, and Virginia culture.

Federal rescheduling is in motion but not finished. Here’s how taxes, banking, hemp, and delivery compliance could shift—and what DC, Maryland, and Virginia should prepare for now.

Discover the legal battles, scientific testing disputes, and regulatory developments surrounding the Church of Sacred Synthesis sacrament.

A legal challenge targeting federal medical marijuana rescheduling survived its initial hurdle, setting up the next phase of policy uncertainty.

As federal agents inspect medical dispensaries registering for Schedule III protections, new DEA inquiries reveal critical compliance guidelines.

The Department of Justice reschedules medical cannabis to Schedule III and schedules June 2026 hearings on adult-use reform. Here is what it means.